Drugs / CoVacHGMix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05526183 | Jan → Dec 2022 | COVID-19 | Ankara City Hospital Bilkent | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoVacHGMix | “The CoVacHGMix adenoviral vector vaccine is a new vaccine developed to protect against SARS-CoV-2” NCT05526183 ↗ |
| Modality | Vaccine | “The CoVacHGMix adenoviral vector vaccine is a new vaccine” NCT05526183 ↗ |
| Route | Intramuscular | “The vaccine will be injected intramuscularly” NCT05526183 ↗ |